PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature
Solid-organ malignancies represent a significant disease burden and remain one of the leading causes of death globally. In the past few decades, the rapid evolution of imaging modalities has shifted the paradigm towards image-based precision medicine, especially in the care of patients with solid-or...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589008590340096 |
|---|---|
| author | Anusha Agarwal Chase J. Wehrle Sangeeta Satish Paresh Mahajan Suneel Kamath Shlomo Koyfman Wen Wee Ma Maureen Linganna Jamak Modaresi Esfeh Charles Miller David C. H. Kwon Andrea Schlegel Federico Aucejo |
| author_facet | Anusha Agarwal Chase J. Wehrle Sangeeta Satish Paresh Mahajan Suneel Kamath Shlomo Koyfman Wen Wee Ma Maureen Linganna Jamak Modaresi Esfeh Charles Miller David C. H. Kwon Andrea Schlegel Federico Aucejo |
| author_sort | Anusha Agarwal |
| collection | DOAJ |
| description | Solid-organ malignancies represent a significant disease burden and remain one of the leading causes of death globally. In the past few decades, the rapid evolution of imaging modalities has shifted the paradigm towards image-based precision medicine, especially in the care of patients with solid-organ malignancies. Metabolic tumor volume (MTV) is one such semi-quantitative parameter obtained from positron emission tomography (PET) imaging with <sup>18</sup>F-fluorodeoxyglucose (FDG) that has been shown to have significant implications in the clinical oncology setting. Across various solid tumor malignancies, including lung cancer, head and neck cancer, breast cancer, esophageal cancer, and colorectal cancer, the current literature has demonstrated an association between MTV and various clinical outcomes. MTV may be used in conjunction with several existing and established clinical parameters to help inform risk stratification and treatment strategies and predict outcomes in cancer. Optimizing such volumetric parameters is paramount for advancing efforts to advance cancer care for our patients. While such advancements are made, it is important to investigate and address the limitations of MTV, including variability in terms of measurement methods, a lack of standardized cut-off values, and the impact of inherent tumor heterogeneity. Despite these limitations, which can precipitate challenges in standardization, MTV as a prognostic factor has great potential and opens an avenue for the future integration of technology into an image-based precision medicine model of care for cancer patients. This article serves as a narrative review and explores the utility and limitations of PET-MTV in various settings of solid-organ malignancy. |
| format | Article |
| id | doaj-art-c95c2d4e8058402fbff108c09a7b5618 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-c95c2d4e8058402fbff108c09a7b56182025-01-24T13:24:05ZengMDPI AGBiomedicines2227-90592025-01-0113112310.3390/biomedicines13010123PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the LiteratureAnusha Agarwal0Chase J. Wehrle1Sangeeta Satish2Paresh Mahajan3Suneel Kamath4Shlomo Koyfman5Wen Wee Ma6Maureen Linganna7Jamak Modaresi Esfeh8Charles Miller9David C. H. Kwon10Andrea Schlegel11Federico Aucejo12Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USADepartment of Radiology, Nuclear Medicine Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USATaussig Cancer Institute, GI Oncology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USATaussig Cancer Institute, Head & Neck Oncology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USATaussig Cancer Institute, GI Oncology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, Hepatology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, Hepatology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USADigestive Diseases and Surgery Institute, HPB and Transplant Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USASolid-organ malignancies represent a significant disease burden and remain one of the leading causes of death globally. In the past few decades, the rapid evolution of imaging modalities has shifted the paradigm towards image-based precision medicine, especially in the care of patients with solid-organ malignancies. Metabolic tumor volume (MTV) is one such semi-quantitative parameter obtained from positron emission tomography (PET) imaging with <sup>18</sup>F-fluorodeoxyglucose (FDG) that has been shown to have significant implications in the clinical oncology setting. Across various solid tumor malignancies, including lung cancer, head and neck cancer, breast cancer, esophageal cancer, and colorectal cancer, the current literature has demonstrated an association between MTV and various clinical outcomes. MTV may be used in conjunction with several existing and established clinical parameters to help inform risk stratification and treatment strategies and predict outcomes in cancer. Optimizing such volumetric parameters is paramount for advancing efforts to advance cancer care for our patients. While such advancements are made, it is important to investigate and address the limitations of MTV, including variability in terms of measurement methods, a lack of standardized cut-off values, and the impact of inherent tumor heterogeneity. Despite these limitations, which can precipitate challenges in standardization, MTV as a prognostic factor has great potential and opens an avenue for the future integration of technology into an image-based precision medicine model of care for cancer patients. This article serves as a narrative review and explores the utility and limitations of PET-MTV in various settings of solid-organ malignancy.https://www.mdpi.com/2227-9059/13/1/123FDG-PET scannuclear medicinemetabolic tumor volume |
| spellingShingle | Anusha Agarwal Chase J. Wehrle Sangeeta Satish Paresh Mahajan Suneel Kamath Shlomo Koyfman Wen Wee Ma Maureen Linganna Jamak Modaresi Esfeh Charles Miller David C. H. Kwon Andrea Schlegel Federico Aucejo PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature Biomedicines FDG-PET scan nuclear medicine metabolic tumor volume |
| title | PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature |
| title_full | PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature |
| title_fullStr | PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature |
| title_full_unstemmed | PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature |
| title_short | PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature |
| title_sort | pet assessed metabolic tumor volume across the spectrum of solid organ malignancies a review of the literature |
| topic | FDG-PET scan nuclear medicine metabolic tumor volume |
| url | https://www.mdpi.com/2227-9059/13/1/123 |
| work_keys_str_mv | AT anushaagarwal petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT chasejwehrle petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT sangeetasatish petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT pareshmahajan petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT suneelkamath petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT shlomokoyfman petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT wenweema petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT maureenlinganna petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT jamakmodaresiesfeh petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT charlesmiller petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT davidchkwon petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT andreaschlegel petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature AT federicoaucejo petassessedmetabolictumorvolumeacrossthespectrumofsolidorganmalignanciesareviewoftheliterature |